-
Global stocks rally on lower oil prices, US-China hopes
-
Spain coach De la Fuente gets new deal after World Cup success
-
EU proposes energy rating for data centres
-
Pressure grows on Germany's Merz after election defeats
-
Schoolgirl Yu scorches to second gold as doping case rocks Games
-
China's Zhang beats Japan rivals to Asian Games gymnastics gold
-
Putin's party secures record score in Russia election
-
Samlingen Haupt: Vad pengar avslöjar om oss människor
-
Haupt Koleksiyonu: Paranın Biz İnsanlar Hakkında Anlattıkları
-
Tens of thousands of German auto workers protest to save jobs
-
Spanish PM says unregulated AI could be 'devastating'
-
हॉप्त् कलेक्शन: पैसा हमारे बारे में एक इंसान के रूप में क्या प्रकट करता है
-
Yu, 13, smashes record again with second Asian Games gold
-
Συλλογή Haupt: Τι αποκαλύπτει το χρήμα για εμάς τους ανθρώπους
-
Switzerland to play without Xhaka over fake Covid certificate
-
TradersYard Shifts Focus to Futures Trading
-
From Korean Chipmakers to Leveraged Semiconductor ETFs: STARTRADER Launches 49 New 24/7 Stock and ETF CFDs
-
ハウプト・コレクション:お金が人間について明かすこと
-
Thai badminton player first doping case at Asian Games: testers
-
하우프트 컬렉션: 돈이 우리 인간에 대해 드러내는 것
-
Колекція Гаупта: Що гроші розповідають про нас, людей
-
Indonesia doing 'everything' but struggling to curb fires
-
German far-right AfD poll winner says Merz 'twilight' has begun
-
Sbírka Haupt: Co o nás lidech prozrazují peníze
-
Flights scrapped, evacuations urged as Typhoon Dujuan nears Japan
-
North and South Korea fight out draw in niggly Asian Games clash
-
China confirms Xi to visit US this week for Trump talks
-
Officials say man shot, wounded by ICE agent in Texas
-
مجموعة هاوبت: ما يكشفه المال عنا نحن البشر
-
豪普特收藏:金錢如何揭露人類的本質
-
Colecția Haupt: Ce ne dezvăluie banii despre noi, oamenii
-
Kolekcja Haupta: Co pieniądze mówią o nas, ludziach
-
Sisters of jailed Pakistan ex-PM Imran Khan arrested
-
The Haupt Collection: What Money Reveals About Us as Human Beings
-
African players in Europe: Semenyo brace helps City top table
-
Barcelona enter new era aiming to retain Women's Champions League crown
-
'For my family': India boxer beats hardship, injury to go for Games gold
-
US has deported 25,000 to third countries under secretive deals: report
-
Indonesia doing 'everything' but still struggling to curb fires
-
Three South Korean soldiers injured in DMZ blast: military
-
Once decried as 'human cockfighting', MMA wants Olympic spot
-
New Zealanders pick endangered black robin as Bird of the Year
-
China's Yu, 13, great for swimming says multiple Olympic medallist
-
Asia stocks rise on AI, US-China trade talks optimism
-
Putin's party set to retain power after Russia vote hit by cyberattacks, drones
-
Malaysia's 'elephant whisperer' fights to save Borneo's endangered giants
-
Germany's Merz under pressure after bruising state election losses
-
'I live in fear': 1.5 million Pakistani children sexually exploited online
-
Messi, Miami frustrated in 2-2 draw with San Diego
-
Cowboys beat Commanders, Vikings down Bears as star QBs injured
First person vaccinated during trial of new Ebola jab
A volunteer was injected on Friday with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola driving a deadly outbreak in the Democratic Republic of Congo, Oxford University said.
More than 1,000 people have been killed in the DRC and Uganda since the outbreak emerged in May, according to the World Health Organization.
Researchers and health organisations have since been racing to get a vaccine or treatment for the relatively rare strain to the clinical trial stage where it is tested on humans.
Earlier this month, a team at Oxford University in the UK announced it was launching the first trial for its ChAdOx1 BDBV vaccine, which uses the same technology as AstraZeneca's Covid-19 vaccine.
The first dose was administered to a 37-year-old volunteer named Ed Hunt in Oxford on Friday, a university spokesman told AFP.
"We've taken this vaccine candidate from concept to clinic in just eight weeks," David Pulido-Gomez of Oxford's Pandemic Sciences Institute said in a statement.
"Reaching this milestone in such a short timeframe reflects an extraordinary collaborative effort," he added.
The trial received funding from the Coalition for Epidemic Preparedness Innovations (CEPI), while the Serum Institute of India has already manufactured a stockpile of 620,000 doses.
The phase 1 trial plans to assess the safety and effectiveness of the vaccine in 50 health adults in the coming weeks. The researchers are currently recruiting more volunteers.
Given regulatory approval, the team is preparing for more clinical studies of the vaccine with partners in Uganda, Oxford said.
Several other Bundibugyo vaccine candidates are also being urgently developed towards the trial stage, while two potential treatments are being worked on.
The Ebola outbreak is the 17th in the DRC's history, but just the third caused by the Bundibugyo strain, for which there are no approved vaccines or treatments.
WHO chief Tedros Adhanom Ghebreyesus warned last week that the outbreak had over the past month "expanded faster than any previous outbreak" of Ebola.
The outbreak has remained concentrated in the vast country's mineral-rich and conflict-plagued northeastern province.
Cases of Ebola, which spreads through close contact and infected bodily fluids, have also been found in four other DRC provinces.
M.Schneider--VB